



Curated by Peter Lansberg,  
a Dutch lipidologist and educator, and  
reviewed by prof. Philip Barter, Past President of the  
International Atherosclerosis Society.

The IAS statin literature update will keep you up to date with all recent statin publications, using a curated approach to select relevant articles.

## Statin Publications October 2021

### Add on treatments

1. Renelus BD, Dixit D, Nguyen PT *et al.* Short-term aspirin and statin chemoprophylaxis did not reduce the risk of developing advanced adenomatous polyps in Black patients. *BMC gastroenterology* 2021; 21:379. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34657610>
2. Parhofer KG. Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful? *Curr Atheroscler Rep* 2021; 23:74. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34648074>
3. Teaima MH, Abdel-Haleem KM, Osama R *et al.* A Promising Single Oral Disintegrating Tablet for Co-Delivery of Pitavastatin Calcium and Lornoxicam Using Co-Processed Excipients: Formulation, Characterization and Pharmacokinetic Study. *Drug design, development and therapy* 2021; 15:4229-4242. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34675486>
4. Ning C, Su S, Li J *et al.* Evaluation of a Clinically Relevant Drug-Drug Interaction Between Rosuvastatin and Clopidogrel and the Risk of Hepatotoxicity. *Frontiers in pharmacology* 2021; 12:715577. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34646133>

5. Bittner V. Treatment Thresholds and ASCVD Risk. J Am Coll Cardiol 2021; 78:1508-1510. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34620407>
6. Gaba P, Bhatt DL, Giugliano RP *et al.* Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. J Am Coll Cardiol 2021; 78:1525-1537. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34620410>
7. Oyama K, Giugliano RP, Blazing MA *et al.* Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. J Am Coll Cardiol 2021; 78:1499-1507. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34620406>
8. Li Y, Narisawa M, Huang Z *et al.* Expanding role for single-pill combination drug therapy in the initial treatment of hypertension? Journal of clinical hypertension (Greenwich, Conn.) 2021; 23:1984-1986. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34657362>
9. Harada H, Nishiyama Y, Niiyama H *et al.* Angiotensin II receptor blocker and statin combination therapy associated with higher skeletal muscle index in patients with cardiovascular disease: A retrospective study. Journal of clinical pharmacy and therapeutics 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34668212>
10. Shin J, Kim H, Yim HW *et al.* Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers: New-onset diabetes mellitus stratified by statin use. Journal of clinical pharmacy and therapeutics 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34668200>
11. Kim K, Bang WD, Han K *et al.* Comparison of the Effects of High-intensity Statin Therapy with Moderate-Intensity Statin and Ezetimibe Combination Therapy on Major Adverse Cardiovascular Events in Patients with Acute Myocardial Infarction: a Nationwide Cohort Study. J Lipid Atheroscler 2021; 10:291-302. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34621700>
12. Kim KJ, Choi J, Kim JY *et al.* Statin Therapy and the Risk of Osteoporotic Fractures in Patients with Metabolic Syndrome: a Nested Case-Control Study. J Lipid Atheroscler 2021; 10:322-333. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34621703>
13. Lee YB, Kim B, Han K *et al.* Combination of Statin and Ezetimibe versus Statin Monotherapy on Cardiovascular Disease and Type 2 Diabetes Incidence among Adults with Impaired Fasting Glucose: a Propensity-Matched Nationwide Cohort Study. J Lipid Atheroscler 2021; 10:303-312. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34621701>
14. Cirillo P, Conte S, Pellegrino G *et al.* Effects of colchicine on tissue factor in oxLDL-activated T-lymphocytes. Journal of thrombosis and thrombolysis 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34671897>
15. Barbălată CI, Porfire AS, Sesarman A *et al.* A Screening Study for the Development of Simvastatin-Doxorubicin Liposomes, a Co-Formulation with Future Perspectives in Colon Cancer Therapy. Pharmaceutics 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34683821>

16. Portela-Romero M, Cinza-Sanjurjo S, Conde-Sabarís P *et al.* Real-life effect on the control of risk factors associated with initiation of the cardiovascular polypill created from equipotent drugs. Rev Clin Esp (Barc) 2021.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34674985>
17. Abdalwahab A, Al-Atta A, Zaman A, Alkhalil M. Intensive lipid-lowering therapy, time to think beyond low-density lipoprotein cholesterol. World J Cardiol 2021; 13:472-482. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34621492>

## Adherence

1. Kristiansen O, Sverre E, Peersen K *et al.* The relationship between directly measured statin adherence, self-reported adherence measures and cholesterol levels in patients with coronary heart disease. Atherosclerosis 2021; 336:23-29.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34610521>
2. Han KT, Choi DW, Kim S. Regional and income disparities in treatment and drug adherence of patients with dyslipidemia: a retrospective cohort study in South Korea, 2003-2015. BMC geriatrics 2021; 21:585.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34674649>
3. Bond Z, Scanlon T, Judah G. Systematic Review of RCTs Assessing the Effectiveness of mHealth Interventions to Improve Statin Medication Adherence: Using the Behaviour-Change Technique Taxonomy to Identify the Techniques That Improve Adherence. Healthcare (Basel) 2021; 9.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34682962>
4. Hickson RP, Annis IE, Killeya-Jones LA, Fang G. Comparing Continuous and Binary Group-based Trajectory Modeling Using Statin Medication Adherence Data. Medical care 2021; 59:997-1005. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34644285>
5. Sabljčić Z, Bašić-Jukić N. Toxic myopathy and liver damage caused by concomitant therapy with remdesivir, atorvastatin, ezetimibe, and tacrolimus in a renal transplant patient with recently treated SARS-CoV-2 induced pneumonia: A case report. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2021.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34676979>
6. Koçak A, Ünlü S, Gökalp G *et al.* The relationship between long-term statin usage and myocardial injury related to percutaneous coronary interventions evaluated by high-sensitivity troponins. Türk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2021; 49:536-544.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34623296>

## Atorvastatin/Rosuvastatin

1. Ikezoe T, Shoji T, Guo J *et al.* No Effect of Hypercholesterolemia on Elastase-Induced Experimental Abdominal Aortic Aneurysm Progression. Biomolecules 2021; 11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34680067>
2. Pope A, Thomson L, Cantu S *et al.* Detection of subclinical atherosclerosis from PET-CT in patients with breast cancer. Journal of cardiovascular computed tomography 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34688578>
3. Zhang X, Chen X, Liang Z *et al.* Atorvastatin Promotes Macrocalcification, But Not Microcalcification in Atherosclerotic Rabbits: An 18F-NaF PET/CT Study. Journal of cardiovascular pharmacology 2021; 78:544-550. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34651601>
4. Orringer CE, Blaha MJ, Stone NJ. Coronary artery calcium scoring in patients with statin associated muscle symptoms: Prescribing statins for those most likely to benefit. J Clin Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34688585>
5. Patel PB, Marcaccio CL, de Guerre L *et al.* Complications after thoracic endovascular aortic repair for ruptured thoracic aortic aneurysms remain high compared with elective repair. Journal of vascular surgery 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34655686>
6. Reiff T, Eckstein HH, Mansmann U *et al.* Successful implementation of best medical treatment for patients with asymptomatic carotid artery stenosis within a randomized controlled trial (SPACE-2). Neurol Res Pract 2021; 3:62. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34666833>
7. Yonezawa Y, Sakuma M, Abe S *et al.* Repeated In-Stent Restenosis Despite Aggressive Lipid Lowering by PCSK-9 Inhibitor Treatment: A Case Report. Tohoku J Exp Med 2021; 255:123-126. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34645737>

## Basic science

1. Agur T, Wedel J, Bose S *et al.* Inhibition of mevalonate metabolism by statins augments the immunoregulatory phenotype of vascular endothelial cells and inhibits the costimulation of CD4(+) T cells. Am J Transplant 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34687147>
2. Nikeafshar S, Khazaei A, Tahvilian R. Inhibition of Methamphetamine-Induced Cytotoxicity in the U87-Cell Line by Atorvastatin-Conjugated Carbon Nanotubes. Appl Biochem Biotechnol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34611858>
3. Shurshalova GS, Scheidt HA, Fischer M *et al.* Interaction of the pitavastatin with model membranes. Biochemistry and biophysics reports 2021; 28:101143. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34632116>
4. Nyambuya TM, Dludla PV, Mxinwa V, Nkambule BB. The pleotropic effects of fluvastatin on complement-mediated T-cell activation in hypercholesterolemia.

- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2021; 143:112224. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34649351>
5. Wang X, Wang D, Xia P *et al.* Ultrasound-targeted simvastatin-loaded microbubble destruction promotes OA cartilage repair by modulating the cholesterol efflux pathway mediated by PPAR $\gamma$  in rabbits. Bone & joint research 2021; 10:693-703. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34666502>
  6. Hussner J, Foletti A, Seibert I *et al.* Differences in transport function of the human and rat orthologue of the Organic Anion Transporting Polypeptide 2B1 (OATP2B1). Drug metabolism and pharmacokinetics 2021; 41:100418. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34628357>
  7. Kwak SY, Jang WI, Park S *et al.* Metallothionein 2 activation by pravastatin reinforces epithelial integrity and ameliorates radiation-induced enteropathy. EBioMedicine 2021; 73:103641. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34688032>
  8. El Sabeih M, Saha SK, Afrin S, Borahay MA. Simvastatin Inhibits Wnt/ $\beta$ -Catenin Pathway in Uterine Leiomyoma. Endocrinology 2021; 162. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34614511>
  9. Afkham S, Hanaee J, Zakariazadeh M *et al.* Molecular mechanism and thermodynamic study of Rosuvastatin interaction with human serum albumin using a surface plasmon resonance method combined with a multi-spectroscopic, and molecular modeling approach. Eur J Pharm Sci 2021; 168:106005. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34688823>
  10. Deng F, Hu JJ, Yang X *et al.* Gut Microbial Metabolite Pravastatin Attenuates Intestinal Ischemia/Reperfusion Injury Through Promoting IL-13 Release From Type II Innate Lymphoid Cells via IL-33/ST2 Signaling. Frontiers in immunology 2021; 12:704836. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34650552>
  11. Clementino AR, Marchi C, Pozzoli M *et al.* Anti-Inflammatory Properties of Statin-Loaded Biodegradable Lecithin/Chitosan Nanoparticles: A Step Toward Nose-to-Brain Treatment of Neurodegenerative Diseases. Frontiers in pharmacology 2021; 12:716380. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34630094>
  12. Gaballah A, Genedy D, Ghayaty E *et al.* Standardized study of atorvastatin possible osteoarthritis disease-modifying effect in a rat model of osteoarthritis. Fundamental & clinical pharmacology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34612533>
  13. Hu N, Chen C, Wang J *et al.* Atorvastatin Ester Regulates Lipid Metabolism in Hyperlipidemia Rats via the PPAR-signaling Pathway and HMGCR Expression in the Liver. Int J Mol Sci 2021; 22. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34681767>
  14. Silva M, Philadelpho B, Santos J *et al.* IAF, QGF, and QDF Peptides Exhibit Cholesterol-Lowering Activity through a Statin-like HMG-CoA Reductase Regulation Mechanism: In Silico and In Vitro Approach. Int J Mol Sci 2021; 22. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34681729>

15. Szlasa W, Kielbik A, Szewczyk A *et al.* Atorvastatin Modulates the Efficacy of Electroporation and Calcium Electrochemotherapy. Int J Mol Sci 2021; 22. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34681903>
16. Zhang X, Chen X, Liang Z *et al.* Atorvastatin Promotes Macrocalcification, But Not Microcalcification in Atherosclerotic Rabbits: An 18F-NaF PET/CT Study. Journal of cardiovascular pharmacology 2021; 78:544-550. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34651601>
17. Yu L, Gao R, Song X *et al.* Cardio-protective and Anti-atherosclerosis Effect of Crocetin on Vitamin D3 and HFD-induced Atherosclerosis in Rats. J Oleo Sci 2021; 70:1447-1459. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34615830>
18. Cirillo P, Conte S, Pellegrino G *et al.* Effects of colchicine on tissue factor in oxLDL-activated T-lymphocytes. Journal of thrombosis and thrombolysis 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34671897>
19. Lai J, Han Y, Huang C *et al.* Non-invasive skin cholesterol testing: a potential proxy for LDL-C and apoB serum measurements. Lipids Health Dis 2021; 20:137. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34657601>
20. Arafat EA, El-Khair SMA, Elsamanoudy AZ, Shabaan DA. Study of the Possible Alleviated Role of Atorvastatin on Irinotecan-Induced Lingual Mucosal Damage: Histological and Molecular Study. Oxidative medicine and cellular longevity 2021; 2021:9690047. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34630855>
21. Cao NT, Nguyen NA, Park CM *et al.* A Novel Statin Compound from Monacolin J Produced Using CYP102A1-Catalyzed Regioselective C-Hydroxylation. Pharmaceuticals (Basel, Switzerland) 2021; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34681205>
22. Abdelkader DH, Abosalha AK, Khattab MA *et al.* A Novel Sustained Anti-Inflammatory Effect of Atorvastatin-Calcium PLGA Nanoparticles: In Vitro Optimization and In Vivo Evaluation. Pharmaceutics 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34683951>
23. Barbălată CI, Porfire AS, Sesarman A *et al.* A Screening Study for the Development of Simvastatin-Doxorubicin Liposomes, a Co-Formulation with Future Perspectives in Colon Cancer Therapy. Pharmaceutics 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34683821>
24. Claesen K, Roth L, Mertens JC *et al.* Pleiotropic Effects of Atorvastatin Result in a Downregulation of the Carboxypeptidase U System (CPU, TAF1a, CPB2) in a Mouse Model of Advanced Atherosclerosis. Pharmaceutics 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34684024>
25. Zhu J, Tan J, Zhang C *et al.* Single Intraosseous Simvastatin Application Induces Endothelial Progenitor Cell Mobilization and Therapeutic Angiogenesis in a Diabetic Hindlimb Ischemia Rat Model. Plastic and reconstructive surgery 2021; 148:936e-945e. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34644264>

26. Andrade-Pavón D, Fernández-Muñoz V, González-Ibarra W *et al.* Point mutations in *Candida glabrata* 3-hydroxy-3-methylglutaryl-coenzyme A reductase (CgHMGR) decrease enzymatic activity and substrate/inhibitor affinity. Scientific reports 2021; 11:20842. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34675283>
27. Moon SJ, Lee SE, Kwak YG, Kim MG. Validation of LC-MS/MS method for determination of rosuvastatin concentration in human blood collected by volumetric absorptive microsampling (VAMS). Translational and clinical pharmacology 2021; 29:125-134. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34621705>
28. Ishikawa T, Osaki T, Sugiura A *et al.* Atorvastatin preferentially inhibits the growth of high ZEB-expressing canine cancer cells. Vet Comp Oncol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34657361>
29. Mahmoud DE, Faraag AHI, Abu El-Wafa WM. In vitro study on the potential fungicidal effects of atorvastatin in combination with some azole drugs against multidrug resistant *Candida albicans*. World journal of microbiology & biotechnology 2021; 37:191. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34632522>

## Cancer

1. Renelus BD, Dixit D, Nguyen PT *et al.* Short-term aspirin and statin chemoprophylaxis did not reduce the risk of developing advanced adenomatous polyps in Black patients. BMC gastroenterology 2021; 21:379. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34657610>
2. Yeh JJ, Lai JN, Lin CL *et al.* Time-dependent propensity-matched general population study of the effects of statin use on cancer risk in an interstitial lung disease and pulmonary fibrosis cohort. BMJ Open 2021; 11:e047039. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34635513>
3. El Sabeh M, Saha SK, Afrin S, Borahay MA. Simvastatin Inhibits Wnt/ $\beta$ -Catenin Pathway in Uterine Leiomyoma. Endocrinology 2021; 162. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34614511>
4. Barbălată CI, Porfire AS, Sesarman A *et al.* A Screening Study for the Development of Simvastatin-Doxorubicin Liposomes, a Co-Formulation with Future Perspectives in Colon Cancer Therapy. Pharmaceutics 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34683821>
5. Ishikawa T, Osaki T, Sugiura A *et al.* Atorvastatin preferentially inhibits the growth of high ZEB-expressing canine cancer cells. Vet Comp Oncol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34657361>

## Children

1. Lewek J, Konopka A, Starostecka E *et al.* Clinical Features of Familial Hypercholesterolemia in Children and Adults in EAS-FHSC Regional Center for

Rare Diseases in Poland. Journal of clinical medicine 2021; 10.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=34640319>

2. Hennig M, Brandt A, Bautembach-Minkowska J *et al.* Erratum to "when do paediatric patients with familial hypercholesterolemia need statin therapy?" (developmental period medicine. 2017;21(1):43-50. DOI: 10.34763/devperiodmed.20172101.4350). J Mother Child 2021; 25:69. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34643350>

## CVD

1. Wu B, Wang Y, Li W *et al.* The effect of rosuvastatin on cardiogenic cerebral infarction. American journal of translational research 2021; 13:9444-9450. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34625005>
2. Ozkalayci F, Türkyılmaz E, Karagoz A *et al.* A Clinical Score to Predict "Corrected Thrombolysis in Myocardial Infarction Frame Count" in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Angiology 2021;33197211045021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34625005>
3. Skrzypiec-Spring M, Sapa-Wojciechowska A, Haczekiewicz-Leśniak K *et al.* HMG-CoA Reductase Inhibitor, Simvastatin Is Effective in Decreasing Degree of Myocarditis by Inhibiting Metalloproteinases Activation. Biomolecules 2021; 11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34680049>
4. Kwon O, Na W, Hur J *et al.* Cardiovascular Event Rates in Statin-Treated Korean Patients with Cardiovascular Disease: Estimates from a Real-World Population Using Electronic Medical Record Data. Cardiovasc Drugs Ther 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34622354>
5. Gong Y, Li X, Ma X *et al.* Lipid goal attainment in post-acute coronary syndrome patients in China: Results from the 6-month real-world dyslipidemia international study II. Clin Cardiol 2021; 44:1575-1585. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34651329>
6. Park CS, Hwang IC, Park JJ *et al.* Determinants of the survival benefit associated with statins in patients with acute heart failure. ESC heart failure 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34612019>
7. Fanta K, Daba FB, Asefa ET *et al.* Management and 30-Day Mortality of Acute Coronary Syndrome in a Resource-Limited Setting: Insight From Ethiopia. A Prospective Cohort Study. Frontiers in cardiovascular medicine 2021; 8:707700. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34604351>
8. Nguyen NT, Chau HN, Le NH *et al.* Impact of Novel Guidelines on Multifactorial Control and Its Association with Mortality in Adult Patients with Hypertension and Newly Diagnosed Type 2 Diabetes: A 4-Year Prospective Multicenter Study. Int J Endocrinol 2021; 2021:9977840. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34621312>



8. Ambrosy AP, Yang J, Sung SH *et al.* Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study. J Am Heart Assoc 2021; 10:e020377.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34622663>
9. Horikoshi T, Nakamura T, Yoshizaki T *et al.* Stratification Analysis of Statin Effect on Major Adverse Cardiac Events after Percutaneous Coronary Intervention in Patients on Hemodialysis. Journal of cardiovascular pharmacology 2021.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34654788>
10. Jia X, Lee MT, Ramsey DJ *et al.* Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the veteran's affairs healthcare system. J Clin Lipidol 2021.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34666951>
11. Lopez D, Nedkoff L, Briffa T *et al.* Effect of frailty on initiation of statins following incident acute coronary syndromes in patients aged  $\geq 75$  years. Maturitas 2021; 153:13-18. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34654523>
12. Chen X, Zhao S, Hsue C *et al.* Effects of aerobic training and resistance training in reducing cardiovascular disease risk for patients with prediabetes: A multi-center randomized controlled trial. Primary care diabetes 2021; 15:1063-1070.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34649825>
13. Alshawwaf M, Delson Molina J, Eltotrki Y *et al.* Cardiovascular risk assessment for patients with serious mental illnesses: An internal review. Qatar Med J 2021; 2021:32. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34604013>

## Endothelium/inflammation

1. Agur T, Wedel J, Bose S *et al.* Inhibition of mevalonate metabolism by statins augments the immunoregulatory phenotype of vascular endothelial cells and inhibits the costimulation of CD4(+) T cells. Am J Transplant 2021.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34687147>
2. Ikezoe T, Shoji T, Guo J *et al.* No Effect of Hypercholesterolemia on Elastase-Induced Experimental Abdominal Aortic Aneurysm Progression. Biomolecules 2021; 11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34680067>
3. Cirillo P, Conte S, Pellegrino G *et al.* Effects of colchicine on tissue factor in oxLDL-activated T-lymphocytes. Journal of thrombosis and thrombolysis 2021.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34671897>
4. Abdelkader DH, Abosalha AK, Khattab MA *et al.* A Novel Sustained Anti-Inflammatory Effect of Atorvastatin-Calcium PLGA Nanoparticles: In Vitro Optimization and In Vivo Evaluation. Pharmaceutics 2021; 13.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34683951>

## Ethnicity

1. Kwon O, Na W, Hur J *et al.* Cardiovascular Event Rates in Statin-Treated Korean Patients with Cardiovascular Disease: Estimates from a Real-World Population Using Electronic Medical Record Data. Cardiovasc Drugs Ther 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34622354>
2. Liu J, Wu YP, Qi JJ *et al.* Effect of Statin Therapy on Diabetes Retinopathy in People With Type 2 Diabetes Mellitus: A Meta-Analysis. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2021; 27:10760296211040109. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34617462>
3. Ambrosy AP, Yang J, Sung SH *et al.* Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study. J Am Heart Assoc 2021; 10:e020377. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34622663>
4. Lee YB, Kim B, Han K *et al.* Combination of Statin and Ezetimibe versus Statin Monotherapy on Cardiovascular Disease and Type 2 Diabetes Incidence among Adults with Impaired Fasting Glucose: a Propensity-Matched Nationwide Cohort Study. J Lipid Atheroscler 2021; 10:303-312. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34621701>
5. Favela-Mendoza AF, Rodríguez-Rodríguez BG, Rojas-Prado E *et al.* Prevalence of protective haplotypes of the SLCO1B1 gene for statin transport in Mexican populations. Personalized medicine 2021; 18:533-540. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34674552>
6. Kim JB, Song WH, Park JS *et al.* Correction: A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia. PLoS One 2021; 16:e0259072. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34669740>
7. Chen X, Zhao S, Hsue C *et al.* Effects of aerobic training and resistance training in reducing cardiovascular disease risk for patients with prediabetes: A multi-center randomized controlled trial. Primary care diabetes 2021; 15:1063-1070. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34649825>

## FH

1. Gatzke LC. Heterozygous Familial Hyperlipidemia in a Fighter Pilot. Aerosp Med Hum Perform 2021; 92:835-837. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34642005>
2. Vuorio A, Strandberg TE, Raal F *et al.* Familial hypercholesterolemia and COVID-19: A menacing but treatable vasculopathic condition. Atheroscler Plus 2021; 43:3-6. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34622243>

3. Nikasa P, Rabbani B, Hejazi MS *et al.* A case of autosomal recessive hypercholesterolemia with a novel mutation in the LDLRAP1 gene. Clin Pediatr Endocrinol 2021; 30:201-204. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34629743>
4. Warden BA, Fazio S, Shapiro MD. Familial Hypercholesterolemia: Genes and Beyond. In: Endotext. Edited by: Feingold KR, Anawalt B, Boyce A *et al.* South Dartmouth (MA): MDText.com, Inc. Copyright © 2000-2021, MDText.com, Inc.; 2000.
5. Rizos CV, Skoumas I, Rallidis L *et al.* LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments. Int J Cardiol 2021; 345:119-124. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34687802>
6. Lewek J, Konopka A, Starostecka E *et al.* Clinical Features of Familial Hypercholesterolemia in Children and Adults in EAS-FHSC Regional Center for Rare Diseases in Poland. Journal of clinical medicine 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34640319>
7. Hennig M, Brandt A, Bautembach-Minkowska J *et al.* Erratum to "when do paediatric patients with familial hypercholesterolemia need statin therapy?" (developmental period medicine. 2017;21(1):43-50. DOI: 10.34763/devperiodmed.20172101.4350). J Mother Child 2021; 25:69. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34643350>

## Genetics

1. Nikasa P, Rabbani B, Hejazi MS *et al.* A case of autosomal recessive hypercholesterolemia with a novel mutation in the LDLRAP1 gene. Clin Pediatr Endocrinol 2021; 30:201-204. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34629743>
2. Merćep I, Radman I, Trkulja V *et al.* Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study. Eur J Clin Pharmacol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34668025>
3. Melhem AL, Chourasia MK, Bigossi M *et al.* Common Statin Intolerance Variants in ABCB1 and LILRB5 Show Synergistic Effects on Statin Response: An Observational Study Using Electronic Health Records. Frontiers in genetics 2021; 12:713181. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34659336>
4. Nguyen NT, Chau HN, Le NH *et al.* Impact of Novel Guidelines on Multifactorial Control and Its Association with Mortality in Adult Patients with Hypertension and Newly Diagnosed Type 2 Diabetes: A 4-Year Prospective Multicenter Study. Int J Endocrinol 2021; 2021:9977840. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34621312>
5. Favela-Mendoza AF, Rodríguez-Rodríguez BG, Rojas-Prado E *et al.* Prevalence of protective haplotypes of the SLCO1B1 gene for statin transport in Mexican populations. Personalized medicine 2021; 18:533-540. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34674552>

6. Andrade-Pavón D, Fernández-Muñoz V, González-Ibarra W *et al.* Point mutations in *Candida glabrata* 3-hydroxy-3-methylglutaryl-coenzyme A reductase (CgHMGR) decrease enzymatic activity and substrate/inhibitor affinity. Scientific reports 2021; 11:20842. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34675283>

## Guidelines

1. Rizos CV, Skoumas I, Rallidis L *et al.* LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments. Int J Cardiol 2021; 345:119-124. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34687802>
2. Behbodikhah J, Ahmed S, Elyasi A *et al.* Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target. Metabolites 2021; 11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34677405>
3. Lovas S, Mahrouseh N, Bolaji OS *et al.* Impact of Policies in Nutrition and Physical Activity on Diabetes and Its Risk Factors in the 28 Member States of the European Union. Nutrients 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34684440>

## LDL- related parameters

1. Peterson KA, Kaur G, Gianos E *et al.* Challenges in Optimizing Lipid Management in Women. Cardiovasc Drugs Ther 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34661802>
2. Mihalj M, Heinisch PP, Huber M *et al.* Effect of Perioperative Lipid Status on Clinical Outcomes after Cardiac Surgery. Cells 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34685697>
3. Chan DC, Ying Q, Watts GF. Recent dynamic studies of the metabolism of atherogenic lipoproteins: elucidating the mode of action of new therapies. Curr Opin Lipidol 2021; 32:378-385. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34636776>
4. Rizos CV, Skoumas I, Rallidis L *et al.* LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments. Int J Cardiol 2021; 345:119-124. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34687802>
5. Silva M, Philadelpho B, Santos J *et al.* IAF, QGF, and QDF Peptides Exhibit Cholesterol-Lowering Activity through a Statin-like HMG-CoA Reductase Regulation Mechanism: In Silico and In Vitro Approach. Int J Mol Sci 2021; 22. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34681729>
6. Lai J, Han Y, Huang C *et al.* Non-invasive skin cholesterol testing: a potential proxy for LDL-C and apoB serum measurements. Lipids Health Dis 2021; 20:137. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34657601>

7. Behbodikhah J, Ahmed S, Elyasi A *et al.* Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target. Metabolites 2021; 11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34677405>
8. Kim JB, Song WH, Park JS *et al.* Correction: A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia. PLoS One 2021; 16:e0259072. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34669740>
9. Abdalwahab A, Al-Atta A, Zaman A, Alkhalil M. Intensive lipid-lowering therapy, time to think beyond low-density lipoprotein cholesterol. World J Cardiol 2021; 13:472-482. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34621492>

## Lifestyle

1. Lovas S, Mahrouseh N, Bolaji OS *et al.* Impact of Policies in Nutrition and Physical Activity on Diabetes and Its Risk Factors in the 28 Member States of the European Union. Nutrients 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34684440>

## Meta-analyses

1. Liu J, Wu YP, Qi JJ *et al.* Effect of Statin Therapy on Diabetes Retinopathy in People With Type 2 Diabetes Mellitus: A Meta-Analysis. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2021; 27:10760296211040109. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34617462>
2. Fatima K, Moeed A, Waqar E *et al.* Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2021:101816. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34607067>
3. Guo Y, Guo X, Zhao K *et al.* Statin Use and Outcomes of Patients With Acute Ischemic Stroke Treated With Intravenous Thrombolysis: A Systematic Review and Meta-Analysis. Frontiers in neurology 2021; 12:734927. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34630305>

## Metabolic Syndrome - Diabetes

1. Chan DC, Ying Q, Watts GF. Recent dynamic studies of the metabolism of atherogenic lipoproteins: elucidating the mode of action of new therapies. Curr Opin Lipidol 2021; 32:378-385. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34636776>
2. Kempegowda P, Chen W, Melson E *et al.* Incidental finding of lipaemia retinalis on diabetic retinal screening. Endocrinol Diabetes Metab Case Rep 2021; 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34673543>

3. Shin J, Kim H, Yim HW *et al.* Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers: New-onset diabetes mellitus stratified by statin use. Journal of clinical pharmacy and therapeutics 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34668200>
4. Lee YB, Kim B, Han K *et al.* Combination of Statin and Ezetimibe versus Statin Monotherapy on Cardiovascular Disease and Type 2 Diabetes Incidence among Adults with Impaired Fasting Glucose: a Propensity-Matched Nationwide Cohort Study. J Lipid Atheroscler 2021; 10:303-312. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34621701>
5. Yu L, Gao R, Song X *et al.* Cardio-protective and Anti-atherosclerosis Effect of Crocetin on Vitamin D3 and HFD-induced Atherosclerosis in Rats. J Oleo Sci 2021; 70:1447-1459. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34615830>
6. Mansi IA, Chansard M, Lingvay I *et al.* Association of Statin Therapy Initiation With Diabetes Progression: A Retrospective Matched-Cohort Study. JAMA Intern Med 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34605849>
7. Lovas S, Mahrouseh N, Bolaji OS *et al.* Impact of Policies in Nutrition and Physical Activity on Diabetes and Its Risk Factors in the 28 Member States of the European Union. Nutrients 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34684440>
8. Chen X, Zhao S, Hsue C *et al.* Effects of aerobic training and resistance training in reducing cardiovascular disease risk for patients with prediabetes: A multi-center randomized controlled trial. Primary care diabetes 2021; 15:1063-1070. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34649825>

## New Treatments

1. Ballarano CA, Frishman WH. Cardiovascular Disease in Patients With Systemic Lupus Erythematosus: Potential for Improved Primary Prevention With Statins. Cardiology in review 2021; 29:323-327. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34609986>
2. Ruscica M, Sirtori CR, Ferri N, Corsini A. New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran. European heart journal supplements : journal of the European Society of Cardiology 2021; 23:E59-e62. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34650356>
3. Silva M, Philadelpho B, Santos J *et al.* IAF, QGF, and QDF Peptides Exhibit Cholesterol-Lowering Activity through a Statin-like HMG-CoA Reductase Regulation Mechanism: In Silico and In Vitro Approach. Int J Mol Sci 2021; 22. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34681729>
4. Mansi IA, Chansard M, Lingvay I *et al.* Association of Statin Therapy Initiation With Diabetes Progression: A Retrospective Matched-Cohort Study. JAMA Intern Med 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34605849>

5. Cao NT, Nguyen NA, Park CM *et al.* A Novel Statin Compound from Monacolin J Produced Using CYP102A1-Catalyzed Regioselective C-Hydroxylation. Pharmaceuticals (Basel, Switzerland) 2021; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34681205>
6. Yonezawa Y, Sakuma M, Abe S *et al.* Repeated In-Stent Restenosis Despite Aggressive Lipid Lowering by PCSK-9 Inhibitor Treatment: A Case Report. Tohoku J Exp Med 2021; 255:123-126. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34645737>
7. Papasotiriou M, Ntrinas T, Savvidaki E *et al.* Treatment of Mixed Dyslipidemia With Alirocumab in a Kidney Transplant Recipient: A Case Report. Transplantation proceedings 2021; 53:2775-2778. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34602294>

## Other

1. Al-Ashwal FY, Sulaiman SAS, Sheikh Ghadzi SM *et al.* Knowledge, attitude, perceived barriers, and practices among pharmacists regarding risk assessment of cardiovascular disease: a cross-sectional study in Yemen. Current medical research and opinion 2021:1-9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34657524>
2. Martini C, Andreoletti M. Genuine versus bogus scientific controversies: the case of statins. Hist Philos Life Sci 2021; 43:110. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34648083>
3. Karampoor S, Hesamizadeh K, Shams Z *et al.* The role of lovastatin in the attenuation of COVID-19. Int Immunopharmacol 2021; 101:108192. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34607230>
4. El-Solh AA, Lawson Y, El-Solh DA. All-cause mortality in COVID-19 patients receiving statin therapy: analysis of veterans affairs database cohort study. Internal and emergency medicine 2021:1-10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34637080>
5. Talasaz AH, Sadeghipour P, Aghakouchakzadeh M *et al.* Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review. J Am Coll Cardiol 2021; 78:1635-1654. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34649702>
6. Memel ZN, Lee JJ, Foulkes AS *et al.* Association of Statins and 28-Day Mortality in Patients Hospitalized with SARS CoV-2 Infection. The Journal of infectious diseases 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34665852>
7. Lee SW, Kim SY, Moon SY *et al.* Statin Use and COVID-19 Infectivity and Severity in South Korea: Two Population-Based Nationwide Cohort Studies. JMIR public health and surveillance 2021; 7:e29379. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34623311>
8. Bergqvist R, Ahlqvist VH, Lundberg M *et al.* HMG-CoA reductase inhibitors and COVID-19 mortality in Stockholm, Sweden: A registry-based cohort study. PLoS Med 2021; 18:e1003820. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34648516>

9. Umakanthan S, Senthil S, John S *et al.* The protective role of statins in COVID-19 patients: a retrospective observational study. Transl Med Commun 2021; 6:22. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34604534>

## **PAD and statins**

1. Paraskevas KI, Mukherjee D, Liapis CD, Veith FJ. Statin Use and Cardiovascular Event/Death Rates after Abdominal Aortic Aneurysm Repair Procedures. Current vascular pharmacology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34602047>
2. Gilchrist IC, Jr., Morrow DA, Creager MA *et al.* Efficacy and Safety of Vorapaxar by Intensity of Background Lipid-Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P-TIMI 50 Trial. J Am Heart Assoc 2021; 10:e021412. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34622665>
3. Patel PB, Marcaccio CL, de Guerre L *et al.* Complications after thoracic endovascular aortic repair for ruptured thoracic aortic aneurysms remain high compared with elective repair. Journal of vascular surgery 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34655686>

## **Pleiotropic effects of statins**

1. Henson JB, Patel YA, Muir AJ. Trends in statin utilisation in US adults with non-alcoholic fatty liver disease. Alimentary pharmacology & therapeutics 2021; 54:1481-1489. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34653272>
2. Smith DD, Costantine MM. Reply: Timing of pravastatin initiation for preeclampsia prevention. American journal of obstetrics and gynecology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34666054>
3. Zhu J, Yan L, Ji JN *et al.* Fluvastatin combined with corbrin capsule can improve depression and anxiety in the treatment of chronic obstructive pulmonary disease. American journal of translational research 2021; 13:10501-10508. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34650720>
4. Agur T, Wedel J, Bose S *et al.* Inhibition of mevalonate metabolism by statins augments the immunoregulatory phenotype of vascular endothelial cells and inhibits the costimulation of CD4(+) T cells. Am J Transplant 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34687147>
5. Nyambuya TM, Dludla PV, Mxinwa V, Nkambule BB. The pleiotropic effects of fluvastatin on complement-mediated T-cell activation in hypercholesterolemia. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2021; 143:112224. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34649351>
6. Skrzypiec-Spring M, Sapa-Wojciechowska A, Haczekwicz-Leśniak K *et al.* HMG-CoA Reductase Inhibitor, Simvastatin Is Effective in Decreasing Degree of



- Myocarditis by Inhibiting Metalloproteinases Activation. Biomolecules 2021; 11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34680049>
7. Renelus BD, Dixit D, Nguyen PT *et al.* Short-term aspirin and statin chemoprophylaxis did not reduce the risk of developing advanced adenomatous polyps in Black patients. BMC gastroenterology 2021; 21:379. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34657610>
  8. Yeh JJ, Lai JN, Lin CL *et al.* Time-dependent propensity-matched general population study of the effects of statin use on cancer risk in an interstitial lung disease and pulmonary fibrosis cohort. BMJ Open 2021; 11:e047039. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34635513>
  9. Wang X, Wang D, Xia P *et al.* Ultrasound-targeted simvastatin-loaded microbubble destruction promotes OA cartilage repair by modulating the cholesterol efflux pathway mediated by PPAR $\gamma$  in rabbits. Bone & joint research 2021; 10:693-703. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34666502>
  10. Fatima K, Moeed A, Waqar E *et al.* Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2021:101816. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34607067>
  11. Kwak SY, Jang WI, Park S *et al.* Metallothionein 2 activation by pravastatin reinforces epithelial integrity and ameliorates radiation-induced enteropathy. EBioMedicine 2021; 73:103641. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34688032>
  12. Deng F, Hu JJ, Yang X *et al.* Gut Microbial Metabolite Pravastatin Attenuates Intestinal Ischemia/Reperfusion Injury Through Promoting IL-13 Release From Type II Innate Lymphoid Cells via IL-33/ST2 Signaling. Frontiers in immunology 2021; 12:704836. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34650552>
  13. Guo Y, Guo X, Zhao K *et al.* Statin Use and Outcomes of Patients With Acute Ischemic Stroke Treated With Intravenous Thrombolysis: A Systematic Review and Meta-Analysis. Frontiers in neurology 2021; 12:734927. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34630305>
  14. Clementino AR, Marchi C, Pozzoli M *et al.* Anti-Inflammatory Properties of Statin-Loaded Biodegradable Lecithin/Chitosan Nanoparticles: A Step Toward Nose-to-Brain Treatment of Neurodegenerative Diseases. Frontiers in pharmacology 2021; 12:716380. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34630094>
  15. Gaballah A, Genedy D, Ghayaty E *et al.* Standardized study of atorvastatin possible osteoarthritis disease-modifying effect in a rat model of osteoarthritis. Fundamental & clinical pharmacology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34612533>
  16. Netyazhenko V, Bazhenova N. THE INFLUENCE OF HYPERCHOLESTEROLEMIA AND CONCOMITANT STATIN THERAPY ON THE STATE OF PLATELET-PLASMA HEMOSTASIS IN PATIENTS WITH ESSENTIAL HYPERTENSION AND NON-ALCOHOLIC FATTY LIVER DISEASE. Georgian medical news 2021:75-81. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34628383>

17. Karampoor S, Hesamizadeh K, Shams Z *et al.* The role of lovastatin in the attenuation of COVID-19. Int Immunopharmacol 2021; 101:108192. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34607230>
18. Sun SH, Chang CH, Zhan ZW *et al.* Risk of COPD Exacerbations Associated with Statins versus Fibrates: A New User, Active Comparison, and High-Dimensional Propensity Score Matched Cohort Study. International journal of chronic obstructive pulmonary disease 2021; 16:2721-2733. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34621122>
19. Szlasa W, Kielbik A, Szewczyk A *et al.* Atorvastatin Modulates the Efficacy of Electroporation and Calcium Electrochemotherapy. Int J Mol Sci 2021; 22. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34681903>
20. Zhao G, Li N, Yin M, Xu M. Atorvastatin (ATV)-Loaded Lipid Bilayer-Coated Mesoporous Silica Nanoparticles Enhance the Therapeutic Efficacy of Acute Kidney Injury. Journal of biomedical nanotechnology 2021; 17:1754-1764. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34688320>
21. Harada H, Nishiyama Y, Niiyama H *et al.* Angiotensin II receptor blocker and statin combination therapy associated with higher skeletal muscle index in patients with cardiovascular disease: A retrospective study. Journal of clinical pharmacy and therapeutics 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34668212>
22. Kim KJ, Choi J, Kim JY *et al.* Statin Therapy and the Risk of Osteoporotic Fractures in Patients with Metabolic Syndrome: a Nested Case-Control Study. J Lipid Atheroscler 2021; 10:322-333. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34621703>
23. Arafat EA, El-Khair SMA, Elsamanoudy AZ, Shabaan DA. Study of the Possible Alleviated Role of Atorvastatin on Irinotecan-Induced Lingual Mucosal Damage: Histological and Molecular Study. Oxidative medicine and cellular longevity 2021; 2021:9690047. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34630855>
24. Barbălată CI, Porfire AS, Sesarman A *et al.* A Screening Study for the Development of Simvastatin-Doxorubicin Liposomes, a Co-Formulation with Future Perspectives in Colon Cancer Therapy. Pharmaceutics 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34683821>
25. Claesen K, Roth L, Mertens JC *et al.* Pleiotropic Effects of Atorvastatin Result in a Downregulation of the Carboxypeptidase U System (CPU, TAF1a, CPB2) in a Mouse Model of Advanced Atherosclerosis. Pharmaceutics 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34684024>
26. Zhu J, Tan J, Zhang C *et al.* Single Intraosseous Simvastatin Application Induces Endothelial Progenitor Cell Mobilization and Therapeutic Angiogenesis in a Diabetic Hindlimb Ischemia Rat Model. Plastic and reconstructive surgery 2021; 148:936e-945e. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34644264>
27. Lee J, Kim JS, Kim Y. Atorvastatin-mediated rescue of cancer-related cognitive changes in combined anticancer therapies. PLoS computational biology 2021; 17:e1009457. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34669701>

28. Umakanthan S, Senthil S, John S *et al*. The protective role of statins in COVID-19 patients: a retrospective observational study. Transl Med Commun 2021; 6:22. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34604534>
29. Okyay K. Pleiotropic effects of statins: New evidences. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2021; 49:533-535. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34623295>
30. Ishikawa T, Osaki T, Sugiura A *et al*. Atorvastatin preferentially inhibits the growth of high ZEB-expressing canine cancer cells. Vet Comp Oncol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34657361>
31. Mahmoud DE, Faraag AHI, Abu El-Wafa WM. In vitro study on the potential fungicidal effects of atorvastatin in combination with some azole drugs against multidrug resistant *Candida albicans*. World journal of microbiology & biotechnology 2021; 37:191. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34632522>

## Primary Prevention

1. Ballarano CA, Frishman WH. Cardiovascular Disease in Patients With Systemic Lupus Erythematosus: Potential for Improved Primary Prevention With Statins. Cardiology in review 2021; 29:323-327. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34609986>
2. Perna GP. Statins and age: is there a limit beyond which primary prevention is futile? European heart journal supplements : journal of the European Society of Cardiology 2021; 23:E109-e111. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34650367>

## Registry data

1. Henson JB, Patel YA, Muir AJ. Trends in statin utilisation in US adults with non-alcoholic fatty liver disease. Alimentary pharmacology & therapeutics 2021; 54:1481-1489. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34653272>
2. Nasir K, Ziffer JA, Cainzos-Achirica M *et al*. The Miami Heart Study (MiHeart) at Baptist Health South Florida, A prospective study of subclinical cardiovascular disease and emerging cardiovascular risk factors in asymptomatic young and middle-aged adults: The Miami Heart Study: Rationale and Design. Am J Prev Cardiol 2021; 7:100202. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34611641>
3. Gong Y, Li X, Ma X *et al*. Lipid goal attainment in post-acute coronary syndrome patients in China: Results from the 6-month real-world dyslipidemia international study II. Clin Cardiol 2021; 44:1575-1585. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34651329>
4. Park CS, Hwang IC, Park JJ *et al*. Determinants of the survival benefit associated with statins in patients with acute heart failure. ESC heart failure 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34612019>

5. Fanta K, Daba FB, Asefa ET *et al.* Management and 30-Day Mortality of Acute Coronary Syndrome in a Resource-Limited Setting: Insight From Ethiopia. A Prospective Cohort Study. Frontiers in cardiovascular medicine 2021; 8:707700. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34604351>
6. Melhem AL, Chourasia MK, Bigossi M *et al.* Common Statin Intolerance Variants in ABCB1 and LILRB5 Show Synergistic Effects on Statin Response: An Observational Study Using Electronic Health Records. Frontiers in genetics 2021; 12:713181. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34659336>
7. Netyazhenko V, Bazhenova N. THE INFLUENCE OF HYPERCHOLESTEROLEMIA AND CONCOMITANT STATIN THERAPY ON THE STATE OF PLATELET-PLASMA HEMOSTASIS IN PATIENTS WITH ESSENTIAL HYPERTENSION AND NON-ALCOHOLIC FATTY LIVER DISEASE. Georgian medical news 2021:75-81. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34628383>
8. Sun SH, Chang CH, Zhan ZW *et al.* Risk of COPD Exacerbations Associated with Statins versus Fibrates: A New User, Active Comparison, and High-Dimensional Propensity Score Matched Cohort Study. International journal of chronic obstructive pulmonary disease 2021; 16:2721-2733. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34621122>
9. El-Solh AA, Lawson Y, El-Solh DA. All-cause mortality in COVID-19 patients receiving statin therapy: analysis of veterans affairs database cohort study. Internal and emergency medicine 2021:1-10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34637080>
10. Ambrosy AP, Yang J, Sung SH *et al.* Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study. J Am Heart Assoc 2021; 10:e020377. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34622663>
11. Horikoshi T, Nakamura T, Yoshizaki T *et al.* Stratification Analysis of Statin Effect on Major Adverse Cardiac Events after Percutaneous Coronary Intervention in Patients on Hemodialysis. Journal of cardiovascular pharmacology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34654788>
12. Jia X, Lee MT, Ramsey DJ *et al.* Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the veteran's affairs healthcare system. J Clin Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34666951>
13. Lewek J, Konopka A, Starostecka E *et al.* Clinical Features of Familial Hypercholesterolemia in Children and Adults in EAS-FHSC Regional Center for Rare Diseases in Poland. Journal of clinical medicine 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34640319>
14. Shin J, Kim H, Yim HW *et al.* Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers: New-onset diabetes mellitus stratified by statin use.

Journal of clinical pharmacy and therapeutics 2021.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=34668200>

15. Haehn DA, Bajalia EM, Gonzalez Albo GA *et al.* Statin use and association with postoperative estimated glomerular filtration rates in patients undergoing robotic-assisted partial nephrectomy. J Endourol 2021.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34663077>
16. Memel ZN, Lee JJ, Foulkes AS *et al.* Association of Statins and 28-Day Mortality in Patients Hospitalized with SARS CoV-2 Infection. The Journal of infectious diseases 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34665852>
17. Kim KJ, Choi J, Kim JY *et al.* Statin Therapy and the Risk of Osteoporotic Fractures in Patients with Metabolic Syndrome: a Nested Case-Control Study. J Lipid Atheroscler 2021; 10:322-333. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34621703>
18. Lee YB, Kim B, Han K *et al.* Combination of Statin and Ezetimibe versus Statin Monotherapy on Cardiovascular Disease and Type 2 Diabetes Incidence among Adults with Impaired Fasting Glucose: a Propensity-Matched Nationwide Cohort Study. J Lipid Atheroscler 2021; 10:303-312.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34621701>
19. Patel PB, Marcaccio CL, de Guerre L *et al.* Complications after thoracic endovascular aortic repair for ruptured thoracic aortic aneurysms remain high compared with elective repair. Journal of vascular surgery 2021.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34655686>
20. Mansi IA, Chansard M, Lingvay I *et al.* Association of Statin Therapy Initiation With Diabetes Progression: A Retrospective Matched-Cohort Study. JAMA Intern Med 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34605849>
21. Lee SW, Kim SY, Moon SY *et al.* Statin Use and COVID-19 Infectivity and Severity in South Korea: Two Population-Based Nationwide Cohort Studies. JMIR public health and surveillance 2021; 7:e29379. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34623311>
22. Koçak A, Ünlü S, Gökalp G *et al.* The relationship between long-term statin usage and myocardial injury related to percutaneous coronary interventions evaluated by high-sensitivity troponins. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2021; 49:536-544.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34623296>

## Renal Disease

1. Hecking M, Karaboyas A, Schernthaner GH, Wanner C. Statin initiation in dialysis patients: The hardship of non-prescription. Atherosclerosis 2021; 337:53-56.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34663493>
2. Zhao G, Li N, Yin M, Xu M. Atorvastatin (ATV)-Loaded Lipid Bilayer-Coated Mesoporous Silica Nanoparticles Enhance the Therapeutic Efficacy of Acute Kidney

- Injury. Journal of biomedical nanotechnology 2021; 17:1754-1764.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34688320>
3. Horikoshi T, Nakamura T, Yoshizaki T *et al.* Stratification Analysis of Statin Effect on Major Adverse Cardiac Events after Percutaneous Coronary Intervention in Patients on Hemodialysis. Journal of cardiovascular pharmacology 2021.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34654788>
  4. Haehn DA, Bajalia EM, Gonzalez Albo GA *et al.* Statin use and association with postoperative estimated glomerular filtration rates in patients undergoing robotic-assisted partial nephrectomy. J Endourol 2021.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34663077>
  5. Sabljic Z, Bašić-Jukić N. Toxic myopathy and liver damage caused by concomitant therapy with remdesivir, atorvastatin, ezetimibe, and tacrolimus in a renal transplant patient with recently treated SARS-CoV-2 induced pneumonia: A case report. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2021.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34676979>
  6. Papatirou M, Ntrinas T, Savvidaki E *et al.* Treatment of Mixed Dyslipidemia With Alirocumab in a Kidney Transplant Recipient: A Case Report. Transplantation proceedings 2021; 53:2775-2778. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34602294>

## Reviews

1. Vuorio A, Strandberg TE, Raal F *et al.* Familial hypercholesterolemia and COVID-19: A menacing but treatable vasculopathic condition. Atheroscler Plus 2021; 43:3-6.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34622243>
2. Hecking M, Karaboyas A, Scherthaner GH, Wanner C. Statin initiation in dialysis patients: The hardship of non-prescription. Atherosclerosis 2021; 337:53-56.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34663493>
3. Parhofer KG. Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful? Curr Atheroscler Rep 2021; 23:74.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34648074>
4. Warden BA, Fazio S, Shapiro MD. Familial Hypercholesterolemia: Genes and Beyond. In: Endotext. Edited by: Feingold KR, Anawalt B, Boyce A *et al.* South Dartmouth (MA): MDText.com, Inc. Copyright © 2000-2021, MDText.com, Inc.; 2000.
5. Bond Z, Scanlon T, Judah G. Systematic Review of RCTs Assessing the Effectiveness of mHealth Interventions to Improve Statin Medication Adherence: Using the Behaviour-Change Technique Taxonomy to Identify the Techniques That Improve Adherence. Healthcare (Basel) 2021; 9.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34682962>

6. Talasaz AH, Sadeghipour P, Aghakouchakzadeh M *et al.* Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review. J Am Coll Cardiol 2021; 78:1635-1654.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34649702>
7. Khanna AD, Taylor MD. Necrotising Myositis - Learnings for a Plastic Surgeon. J Plast Reconstr Aesthet Surg 2021.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34635455>
8. Okay K. Pleiotropic effects of statins: New evidences. Turk Kardiyoloji Derneği arsivi : Turk Kardiyoloji Derneginin yayin organidir 2021; 49:533-535.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34623295>
9. Abdalwahab A, Al-Atta A, Zaman A, Alkhalil M. Intensive lipid-lowering therapy, time to think beyond low-density lipoprotein cholesterol. World J Cardiol 2021; 13:472-482. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34621492>

### Safety and side effects

1. Kimoto E, Costales C, West MA *et al.* Biomarker-Informed Model-Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug-Drug Interactions. Clinical pharmacology and therapeutics 2021.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34605015>
2. Teaima MH, Abdel-Haleem KM, Osama R *et al.* A Promising Single Oral Disintegrating Tablet for Co-Delivery of Pitavastatin Calcium and Lornoxicam Using Co-Processed Excipients: Formulation, Characterization and Pharmacokinetic Study. Drug design, development and therapy 2021; 15:4229-4242.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34675486>
3. Hussner J, Foletti A, Seibert I *et al.* Differences in transport function of the human and rat orthologue of the Organic Anion Transporting Polypeptide 2B1 (OATP2B1). Drug metabolism and pharmacokinetics 2021; 41:100418.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34628357>
4. Jessurun NT, Drent M, Wijnen PA *et al.* Role of Drug-Gene Interactions and Pharmacogenetics in Simvastatin-Associated Pulmonary Toxicity. Drug Saf 2021; 44:1179-1191. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34606062>
5. Park CS, Hwang IC, Park JJ *et al.* Determinants of the survival benefit associated with statins in patients with acute heart failure. ESC heart failure 2021.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34612019>
6. Merćep I, Radman I, Trkulja V *et al.* Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study. Eur J Clin Pharmacol 2021.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34668025>
7. Melhem AL, Chourasia MK, Bigossi M *et al.* Common Statin Intolerance Variants in ABCB1 and LILRB5 Show Synergistic Effects on Statin Response: An

- Observational Study Using Electronic Health Records. Frontiers in genetics 2021; 12:713181. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34659336>
8. Guo Y, Guo X, Zhao K *et al.* Statin Use and Outcomes of Patients With Acute Ischemic Stroke Treated With Intravenous Thrombolysis: A Systematic Review and Meta-Analysis. Frontiers in neurology 2021; 12:734927. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34630305>
  9. Ning C, Su S, Li J *et al.* Evaluation of a Clinically Relevant Drug-Drug Interaction Between Rosuvastatin and Clopidogrel and the Risk of Hepatotoxicity. Frontiers in pharmacology 2021; 12:715577. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34646133>
  10. Scott L, Redaniel MT, Booker M *et al.* Regression discontinuity analysis for pharmacovigilance: statin example reflected trial findings showing little evidence of harm. J Clin Epidemiol 2021; 141:121-131. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34648942>
  11. Jia X, Lee MT, Ramsey DJ *et al.* Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the veteran's affairs healthcare system. J Clin Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34666951>
  12. Orringer CE, Blaha MJ, Stone NJ. Coronary artery calcium scoring in patients with statin associated muscle symptoms: Prescribing statins for those most likely to benefit. J Clin Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34688585>
  13. Shin J, Kim H, Yim HW *et al.* Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers: New-onset diabetes mellitus stratified by statin use. Journal of clinical pharmacy and therapeutics 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34668200>
  14. Haehn DA, Bajalia EM, Gonzalez Albo GA *et al.* Statin use and association with postoperative estimated glomerular filtration rates in patients undergoing robotic-assisted partial nephrectomy. J Endourol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34663077>
  15. Yao X, Xie R, Cao Y *et al.* Simvastatin induced ferroptosis for triple-negative breast cancer therapy. J Nanobiotechnology 2021; 19:311. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34627266>
  16. Khanna AD, Taylor MD. Necrotising Myositis - Learnings for a Plastic Surgeon. J Plast Reconstr Aesthet Surg 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34635455>
  17. Mansi IA, Chansard M, Lingvay I *et al.* Association of Statin Therapy Initiation With Diabetes Progression: A Retrospective Matched-Cohort Study. JAMA Intern Med 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34605849>
  18. Favela-Mendoza AF, Rodríguez-Rodríguez BG, Rojas-Prado E *et al.* Prevalence of protective haplotypes of the SLCO1B1 gene for statin transport in Mexican populations. Personalized medicine 2021; 18:533-540. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34674552>



19. Hanke N, Gómez-Mantilla JD, Ishiguro N *et al.* Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions. Pharm Res 2021; 38:1645-1661.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34664206>
20. Kim JB, Song WH, Park JS *et al.* Correction: A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia. PLoS One 2021; 16:e0259072. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34669740>
21. Sabljic Z, Bašić-Jukić N. Toxic myopathy and liver damage caused by concomitant therapy with remdesivir, atorvastatin, ezetimibe, and tacrolimus in a renal transplant patient with recently treated SARS-CoV-2 induced pneumonia: A case report. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2021.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34676979>

## Stroke and CNS

1. Clementino AR, Marchi C, Pozzoli M *et al.* Anti-Inflammatory Properties of Statin-Loaded Biodegradable Lecithin/Chitosan Nanoparticles: A Step Toward Nose-to-Brain Treatment of Neurodegenerative Diseases. Frontiers in pharmacology 2021; 12:716380. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34630094>
2. Reiff T, Eckstein HH, Mansmann U *et al.* Successful implementation of best medical treatment for patients with asymptomatic carotid artery stenosis within a randomized controlled trial (SPACE-2). Neurol Res Pract 2021; 3:62.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34666833>
3. Lee J, Kim JS, Kim Y. Atorvastatin-mediated rescue of cancer-related cognitive changes in combined anticancer therapies. PLoS computational biology 2021; 17:e1009457. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34669701>

## Triglycerides/HDL

1. Darabi M, Kontush A. High-density lipoproteins (HDL): Novel function and therapeutic applications. Biochimica et biophysica acta. Molecular and cell biology of lipids 2022; 1867:159058. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34624514>
2. Mihalj M, Heinisch PP, Huber M *et al.* Effect of Perioperative Lipid Status on Clinical Outcomes after Cardiac Surgery. Cells 2021; 10.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34685697>
3. Bittner V. Treatment Thresholds and ASCVD Risk. J Am Coll Cardiol 2021; 78:1508-1510. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34620407>

4. Gaba P, Bhatt DL, Giugliano RP *et al.* Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. J Am Coll Cardiol 2021; 78:1525-1537. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34620410>
5. Ambrosy AP, Yang J, Sung SH *et al.* Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study. J Am Heart Assoc 2021; 10:e020377. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34622663>
6. Chen X, Zhao S, Hsue C *et al.* Effects of aerobic training and resistance training in reducing cardiovascular disease risk for patients with prediabetes: A multi-center randomized controlled trial. Primary care diabetes 2021; 15:1063-1070. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34649825>
7. Papatotiriou M, Ntrinas T, Savvidaki E *et al.* Treatment of Mixed Dyslipidemia With Alirocumab in a Kidney Transplant Recipient: A Case Report. Transplantation proceedings 2021; 53:2775-2778. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34602294>

## **Trials**

1. Aldika Akbar MI, Yosediputra A, Eri Pratama R *et al.* INOVASIA Study: A Randomized Open Controlled Trial to Evaluate Pravastatin to Prevent Preeclampsia and its Effects on sFlt1/PLGF Levels. Am J Perinatol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34666379>
2. Kristiansen O, Sverre E, Peersen K *et al.* The relationship between directly measured statin adherence, self-reported adherence measures and cholesterol levels in patients with coronary heart disease. Atherosclerosis 2021; 336:23-29. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34610521>
3. Renelus BD, Dixit D, Nguyen PT *et al.* Short-term aspirin and statin chemoprophylaxis did not reduce the risk of developing advanced adenomatous polyps in Black patients. BMC gastroenterology 2021; 21:379. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34657610>
4. Perna GP. Statins and age: is there a limit beyond which primary prevention is futile? European heart journal supplements : journal of the European Society of Cardiology 2021; 23:E109-e111. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34650367>
5. Bittner V. Treatment Thresholds and ASCVD Risk. J Am Coll Cardiol 2021; 78:1508-1510. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34620407>
6. Gaba P, Bhatt DL, Giugliano RP *et al.* Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. J Am Coll Cardiol 2021; 78:1525-1537. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34620410>
7. Oyama K, Giugliano RP, Blazing MA *et al.* Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in

- IMPROVE-IT. J Am Coll Cardiol 2021; 78:1499-1507.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34620406>
8. Gilchrist IC, Jr., Morrow DA, Creager MA *et al.* Efficacy and Safety of Vorapaxar by Intensity of Background Lipid-Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P-TIMI 50 Trial. J Am Heart Assoc 2021; 10:e021412. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34622665>
  9. Scott L, Redaniel MT, Booker M *et al.* Regression discontinuity analysis for pharmacovigilance: statin example reflected trial findings showing little evidence of harm. J Clin Epidemiol 2021; 141:121-131.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34648942>
  10. Kim K, Bang WD, Han K *et al.* Comparison of the Effects of High-intensity Statin Therapy with Moderate-Intensity Statin and Ezetimibe Combination Therapy on Major Adverse Cardiovascular Events in Patients with Acute Myocardial Infarction: a Nationwide Cohort Study. J Lipid Atheroscler 2021; 10:291-302.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34621700>
  11. Reese PP, Barankay I, Putt M *et al.* Effect of Financial Incentives for Process, Outcomes, or Both on Cholesterol Level Change: A Randomized Clinical Trial. JAMA network open 2021; 4:e2121908.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34605920>
  12. Reiff T, Eckstein HH, Mansmann U *et al.* Successful implementation of best medical treatment for patients with asymptomatic carotid artery stenosis within a randomized controlled trial (SPACE-2). Neurol Res Pract 2021; 3:62.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34666833>
  13. Chen X, Zhao S, Hsue C *et al.* Effects of aerobic training and resistance training in reducing cardiovascular disease risk for patients with prediabetes: A multi-center randomized controlled trial. Primary care diabetes 2021; 15:1063-1070.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34649825>
  14. Portela-Romero M, Cinza-Sanjurjo S, Conde-Sabarís P *et al.* Real-life effect on the control of risk factors associated with initiation of the cardiovascular polypill created from equipotent drugs. Rev Clin Esp (Barc) 2021.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34674985>

## Women and elderly

1. Aschenbrenner DS. Statins No Longer Contraindicated in Pregnancy. The American journal of nursing 2021; 121:22. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34673690>
2. Smith DD, Costantine MM. Reply: Timing of pravastatin initiation for preeclampsia prevention. American journal of obstetrics and gynecology 2021.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34666054>
3. Aldika Akbar MI, Yosedi Putra A, Eri Pratama R *et al.* INOVASIA Study: A Randomized Open Controlled Trial to Evaluate Pravastatin to Prevent Preeclampsia

and its Effects on sFlt1/PLGF Levels. Am J Perinatol 2021.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=34666379>

4. Peterson KA, Kaur G, Gianos E *et al.* Challenges in Optimizing Lipid Management in Women. Cardiovasc Drugs Ther 2021.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34661802>
5. Perna GP. Statins and age: is there a limit beyond which primary prevention is futile? European heart journal supplements : journal of the European Society of Cardiology 2021; 23:E109-e111. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34650367>
6. Lopez D, Nedkoff L, Briffa T *et al.* Effect of frailty on initiation of statins following incident acute coronary syndromes in patients aged  $\geq 75$  years. Maturitas 2021; 153:13-18. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34654523>
7. Ioffe M, Kremer A, Nachimov I *et al.* Mortality associated with stopping statins in the oldest-old - with and without ischemic heart disease. Medicine (Baltimore) 2021; 100:e26966. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34664827>